Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657707 | 0.89 | HTR1A (0.59) | OPRM1HTR1AHTR2ADRD2HRH3 | |
| SCHEMBL5655939 | 0.87 | OPRM1 (0.57) | OPRM1HTR1AHRH3SMN1; SMN2HTR7 | |
| SCHEMBL5657762 | 0.87 | HRH3 (0.52) | OPRM1HTR1AHTR2ADRD2HRH3 | |
| SCHEMBL5657181 | 0.85 | OPRM1 (0.54) | OPRM1HTR1AHTR2ADRD2HRH3 | |
| SCHEMBL5656060 | 0.85 | OPRM1 (0.48) | OPRM1HTR1AHTR2ADRD2HRH3 | |
| SCHEMBL5657865 | 0.84 | OPRM1 (0.47) | OPRM1HTR1AHTR2ADRD2HRH3 | |
| SCHEMBL5656932 | 0.83 | OPRM1 (0.46) | OPRM1HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL5658247 | 0.83 | HTR1A (0.53) | HTR1AHTR2ADRD2HRH3SMN1; SMN2 | |
| SCHEMBL5654884 | 0.82 | DRD2 (0.61) | HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL5655833 | 0.82 | OPRM1 (0.55) | OPRM1HTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | claimed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | OPRM1 242/4885HTR1A 8/4885HTR2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.